Abstract:(1) Background: lung cancer is the world's deadliest cancer, but early diagnosis helps to improve the cure rate and thus reduce the mortality rate. Annual low-dose computed tomography (LD-CT) screening is an efficient lung cancer-screening program for a high-risk population. However, LD-CT has often been characterized by a higher degree of false-positive results. To meet these challenges, a volatolomic approach, in particular, the breath volatile organic compounds (VOCs) fingerprint analysis, has recently received increased attention for its application in early lung cancer screening thanks to its convenience, non-invasiveness, and being well tolerated by patients. (2) Methods: a LC-MS/MS-based volatolomics analysis was carried out according to P/N 5046800 standard based breath analysis of VOC as novel cancer biomarkers for distinguishing early-stage lung cancer from the healthy control group. The discriminatory accuracy of identified VOCs was assessed using subject work characterization and a random forest risk prediction model. (3) Results: the proposed technique has good performance compared with existing approaches, the differences between the exhaled VOCs of the early lung cancer patients before operation, three to seven days after the operation, as well as four to six weeks after operation under fasting and 1 h after the meal were compared with the healthy controls. The results showed that only 1 h after a meal, the concentration of seven VOCs, including 3-hydroxy-2-butanone (TG-4), glycolaldehyde (TG-7), 2-pentanone (TG-8), acrolein (TG-11), nonaldehyde (TG-19), decanal (TG-20), and crotonaldehyde (TG-22), differ significantly between lung cancer patients and control, with the invasive adenocarcinoma of the lung (IAC) having the most significant difference. (4) Conclusions: this novel, non-invasive approach can improve the detection rate of early lung cancer, and LC-MS/MS-based breath analysis could be a promising method for clinical application.

Ambient mass spectrometry for fast identification of lung cancer

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

Ambient Mass Spectrometry for the Molecular Diagnosis of Lung Cancer.

Optimization of Volatile Markers of Lung Cancer to Exclude Interferences of Non-Malignant Disease

In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging

Diagnosis of Non-Small Cell Lung Cancer by Rapid Metabolic Fingerprinting of Sputum Samples Using Neutral Desorption Extractive Electrospray Ionization Tandem Mass Spectrometry

Tissue spray ionization mass spectrometry for rapid recognition of human lung squamous cell carcinoma

Application of Laser Capture Microdissection and Surface-enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Biomarkers for Early Diagnosis of Lung Adenocarcinoma

Lipids in Surgical Aerosol As Diagnosis Biomarkers for Discrimination of Lung Cancer.

LC-MS/MS Based Volatile Organic Compound Biomarkers Analysis for Early Detection of Lung Cancer

Direct quantitative profiling of amino acids in tissues for the assessment of lung cancer

The research on early detection of lung cancer with exhaled volatile organic compounds

High-Throughput Salivary Metabolite Profiling on an Ultralow Noise Tip-Enhanced Laser Desorption Ionization Mass Spectrometry Platform for Noninvasive Diagnosis of Early Lung Cancer.

Neutral Desorption Extractive Electrospray Ionization Mass Spectrometry Analysis Sputum for Non-Invasive Lung Adenocarcinoma Detection

Advancing Lung Cancer Diagnosis through NH 2 -MON-SPME-GC-MS/MS: Enhanced Sensitivity in Aldehyde Biomarker Detection from Exhaled Breath

MALDI Profiling MS Application to Analysis of Non-small Cell Lung Cancer

Mass Spectrometric Discrimination of Human Lung Tumors under Ambient Conditions Based on Random Forest Algorithm

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Advancing Lung Cancer Diagnosis through NH2-MON-SPME-GC-MS/MS: Enhanced Sensitivity in Aldehyde Biomarker Detection from Exhaled Breath

Point-of-Care Tissue Analysis Using Miniature Mass Spectrometer

Non-Small Cell Lung Cancer Detection and Subtyping by UPLC-HRMS-Based Tissue Metabolomics